Malignant neoplasm of thyroid
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The mixed expression of BRAF under varying levels of differentiation may explain, in part, the contradictory studies regarding the impact of BRAF mutations on patient prognosis and also indicates a complex genomic signature for dedifferentiated thyroid cancer.
|
31229486 |
2019 |
Malignant neoplasm of thyroid
|
0.400 |
Biomarker
|
disease |
BEFREE |
Lysyl Oxidase Is a Key Player in BRAF/MAPK Pathway-Driven Thyroid Cancer Aggressiveness.
|
30398411 |
2019 |
Malignant neoplasm of thyroid
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Although most of the US Food and Drug Administration (FDA)-approved drugs are antiangiogenic multikinase inhibitors-vandetanib, cabozantinib, sorafenib, lenvatinib-there are two FDA indications that are mutation specific-dabrafenib/trametinib for BRAF-mutated anaplastic thyroid cancer and larotrectinib for NTRK-fusion thyroid cancer.
|
31322645 |
2019 |
Malignant neoplasm of thyroid
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
BRAF V600E mutations are common in papillary thyroid carcinoma (PTC) and some de-differentiated thyroid cancers.
|
31529211 |
2019 |
Malignant neoplasm of thyroid
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We further demonstrate that upfront combined inhibition of FAK and Src synergistically inhibits growth and invasion, and induces apoptosis in a panel of BRAF- and RAS-mutant thyroid cancer cell lines.
|
30531837 |
2019 |
Malignant neoplasm of thyroid
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, glycolysis-related enzymes, such as LDHA and PKM2, were upregulated in BRAF V600E mutant thyroid cancer specimens, thereby promoting glycolysis.
|
30768848 |
2019 |
Malignant neoplasm of thyroid
|
0.400 |
Biomarker
|
disease |
BEFREE |
Combination strategies involving immune checkpoint inhibitors (ICIs) with tyrosine kinase (TK) or serine/threonine protein kinase B-raf (BRAF) inhibitors are showing considerable promise in the treatment of advanced thyroid cancer.
|
31412566 |
2019 |
Malignant neoplasm of thyroid
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Patients with RAIR, BRAF mutant thyroid cancer.
|
30256977 |
2019 |
Malignant neoplasm of thyroid
|
0.400 |
Biomarker
|
disease |
BEFREE |
BRAFi inhibited ERK signaling in BRAF<sup>V600E</sup> mutants, but not BRAF wild-type thyroid cancer cell lines.
|
31097454 |
2019 |
Malignant neoplasm of thyroid
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Hence, recent research efforts have been performed trying to explore several inhibitors of the V600E mutation-containing BRAF kinase as potential therapeutic options in thyroid cancer refractory to standard interventions.
|
30481266 |
2019 |
Malignant neoplasm of thyroid
|
0.400 |
Biomarker
|
disease |
BEFREE |
BRAF Inhibitors in Thyroid Cancer: Clinical Impact, Mechanisms of Resistance and Future Perspectives.
|
31540406 |
2019 |
Malignant neoplasm of thyroid
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
BRAF-targeted paired box gene-8 (PAX8), a thyroid-specific transcription factor, generally dysregulated in BRAF-mutated thyroid cancer.
|
30760304 |
2019 |
Malignant neoplasm of thyroid
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, the results of the current study suggest that BRAF<sup>V600E</sup>-induced KRT19 expression may promote thyroid cancer metastasis via EMT.
|
31289571 |
2019 |
Malignant neoplasm of thyroid
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our results demonstrate a strong clinical potential for the combination of the Bortezomib and the BRAF inhibitor Vemurafenib as an efficient therapeutic approach for the treatment of TC.
|
29269566 |
2018 |
Malignant neoplasm of thyroid
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
TERT promoter mutations were likely to occur in BRAF V600E positive TC.
|
30024548 |
2018 |
Malignant neoplasm of thyroid
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therefore, we examined the efficacy of the combination therapy across a panel of thyroid cancer cell lines representing common oncogenic drivers (BRAF, RAS, and PIK3CA).
|
29487290 |
2018 |
Malignant neoplasm of thyroid
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
However, the response to vemurafenib is limited in BRAF-mutant thyroid cancer.
|
29737325 |
2018 |
Malignant neoplasm of thyroid
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This study explores the possibility of building AI models without precise pixel-level annotation in prediction of the tumor size, extrathyroidal extension, lymph node metastasis, cancer stage and BRAF mutation in thyroid cancer diagnosis, providing the patients' background information, histopathological and immunohistochemical tissue images.
|
29293907 |
2018 |
Malignant neoplasm of thyroid
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Unusually long-term responses to vemurafenib in BRAF V600E mutated colon and thyroid cancers followed by the development of rare RAS activating mutations.
|
30036146 |
2018 |
Malignant neoplasm of thyroid
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
TERT promoter mutations and their correlation with BRAF and RAS mutations in a consecutive cohort of 145 thyroid cancer cases.
|
29435002 |
2018 |
Malignant neoplasm of thyroid
|
0.400 |
Biomarker
|
disease |
BEFREE |
It was revealed that BRAF<sup>V600E</sup> was present in ~34% of thyroid cancer cases and was associated with age, clinical tumor stage and lymph node stage.
|
29805692 |
2018 |
Malignant neoplasm of thyroid
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Papillary thyroid cancer (PTC) accounts for more than 97 % of thyroid cancer and 80% or more PTC cases harbor the BRAF mutation in Korea.
|
28258306 |
2018 |
Malignant neoplasm of thyroid
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The identification of BRAF mutations in thyroid cancer has prognostic and therapeutic implications.
|
29579361 |
2018 |
Malignant neoplasm of thyroid
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A selective inhibitor of BRAF V600E has been proposed as a novel treatment for patients with thyroid cancer exhibiting BRAF V600E mutations.
|
29616135 |
2018 |
Malignant neoplasm of thyroid
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Specimens of pituitary adenomas and thyroid cancer were collected for BRAF mutation assessments.
|
29593792 |
2018 |